Moleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases. the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. This should be an interesting year for MBRX, which...
Is $MBRX- The Best Biotech with the most upside Potential Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the...
Strong runner today off of some positive news, and the float sits just under 17M! I'll be watching this one for a possible continuation trade tomorrow!
MBRX is in the middle of a correction after the previous big wave up. I'm expecting one more wave down before a potential big wave up. A breakout on the upper trendline invalidates this setup.
MBRX technical chart with momo potential